The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Today’s studies explore adding nimotuzumab to chemotherapy to treat KRAS wild-type pancreatic cancer and adding ibrutinib to standard care for older adults with mantle cell lymphoma. Read More >>
meetings
June 3, 2022 · Greg Guthrie, ASCO staff
June 2, 2022 · Jyoti Patel, MD, FASCO
In this month’s “From the Editor in Chief” column, Dr. Jyoti Patel discusses the return of the American Society of Clinical Oncology (ASCO) Annual Meeting in person and online, and why bringing oncology professionals, researchers, advocates, and people with cancer back together is so important for cancer care. Read More >>
May 26, 2022 · Greg Guthrie, ASCO Staff
The 2022 ASCO Annual Meeting is being held June 3 to 7. In this early release of research being presented at the meeting, studies examine how race, ethnicity, poverty, and other social and demographic factors affect the lives of people with cancer. Read More >>
May 26, 2022 · Greg Guthrie, ASCO Staff
La Reunión Anual de la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica) de 2022 se llevará a cabo del 3 al 7 de junio. En esta publicación inicial de la investigación que se presenta en la reunión, los estudios examinan cómo la raza, el origen étnico, la pobreza y otros factores sociales y demográficos afectan la vida de las personas con cáncer. Read More >>
April 18, 2022 · Greg Guthrie, ASCO staff
Read research from the April 2022 session of the ASCO Plenary Series, which highlights a clinical trial that studied a medication called tislelizumab combined with chemotherapy to treat recurrent or metastatic nasopharyngeal cancer. Read More >>
Pages
- « first page
- ‹ previous page
- …
- page 5
- page 6
- page 7
- page 8
- 9 current page
- page 10
- page 11
- page 12
- page 13
- …
- next page ›
- last page »